Researchers Win Shaw Prize for Leukemia Breakthrough

Chen Zhu, Anne Dejean and Hugues de Thé receive the 2026 Shaw Prize in Life Science and Medicine for work on Acute Promyelocytic Leukaemia.

Updated on Nov. 18, 2026 in Cancer

Researchers Win Shaw Prize for Leukemia Breakthrough

Chen Zhu, Anne Dejean and Hugues de Thé received the 2026 Shaw Prize in Life Science and Medicine at a ceremony in Hong Kong for research on Acute Promyelocytic Leukaemia (APL). Their work produced the Shanghai Protocol, now the standard worldwide treatment for the disease.

Why it matters

In the early 1980s, an APL diagnosis carried an 80 percent risk of death, while more than 90 percent of patients now survive beyond five years. The recognition highlights how an alternative approach drawing on traditional Chinese philosophy helped transform treatment for a once-fatal cancer.

Reported survival rates for APL patients now exceed 90 percent beyond five years, compared with an 80 percent risk of death at diagnosis in the early 1980s. Whether the approach can be applied to other cancers remains unknown, a question Chen Zhu hopes to see answered.

The players

Shaw Prize

The Shaw Prize is an international award recognizing achievements in astronomy, life science and medicine, and mathematical sciences.

Chen Zhu

Chen Zhu is the second Chinese national to receive the Shaw Prize in Life Science and Medicine, for research leading to the Shanghai Protocol.

The details

The Shanghai Protocol combines arsenic trioxide with All-Trans Retinoic Acid, a derivative of vitamin A, to encourage abnormal leukaemia cells to mature into normal blood cells. A five-year-old girl with APL achieved complete remission within weeks of treatment.

Timeline

  1. Early 1980s: Chen Zhu begins research on APL, when diagnosis carried an 80 percent risk of death.

  2. 2026: The Shaw Prize in Life Science and Medicine is awarded to the researchers in Hong Kong.

Health Landscape

The Shanghai Protocol, which combines arsenic trioxide with All-Trans Retinoic Acid, has become the standard worldwide treatment for Acute Promyelocytic Leukaemia. The recognition places a Chinese-developed regimen at the center of modern leukemia care.

For patients diagnosed with APL, the Shanghai Protocol offers a treatment regimen that now supports survival beyond five years for more than 90 percent of those treated. The approach shows how targeted therapy can change outcomes for a disease that once carried a high risk of death at diagnosis.

The takeaway

The Shanghai Protocol shows how research drawing on different scientific traditions can produce treatments that become the global standard. Patients facing APL today have survival prospects far better than those diagnosed four decades ago.

Further reading

Explore more in Cancer.

Source note: This article includes information reported by Cgtn.